ACHV
Achieve Life Sciences Inc.
Achieve Life Sciences Inc.
$ACHV reports FY 2022 financial results & highlights, including updates on cytisinicline trials and patent grant
Achieve Life Sciences has reported its financial results for Q4 and year-end 2022 with a total net loss of $42.4 million for the year. The company has recently completed Phase 2 trial ORCA-V1, dosed the last subject for Phase 3 trial ORCA-3, and had a patent granted by USPTO for new cytisinicline formulation. Management believes that cytisinicline has the potential to help millions of people overcome nicotine addiction. Achieve will continue to deliver on its key milestones leveraging its patents and gross proceeds of approximately $18.9 million. Achieve plans to announce topline results from its ongoing trials in the second quarter of 2023. Investors must take into account the global epidemic of nicotine addiction responsible for eight million deaths worldwide and nearly half a million deaths in the US annually. The FDA has not approved the use of cytisinicline in the United States.
14d ago
$ACHV